Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Genitourinary 1

Conditions

Multiple Myeloma 1Immunoglobulin Light-chain Amyloidosis 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 606Cyclophosphamide 546Magnetic Resonance Spectroscopy 527Radiotherapy 514Specimen Handling 506Nivolumab 412Cisplatin 381Carboplatin 369Biopsy 306Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 270Standard of Care 267Drug Therapy 264fludarabine 263Dexamethasone 263Bevacizumab 253venetoclax 251Oxaliplatin 209Capecitabine 201Rituximab 199Radiation 192Fluorouracil 189Ipilimumab 188durvalumab 185Doxorubicin 179Etoposide 177atezolizumab 175

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × MLN2238 × 1 year × Clear all
NCT03763162 2026-04-15

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
40 enrolled
Plasma cell

Multiple Myeloma

NCT03283917 2026-02-27

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
21 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03587662 2026-01-09

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡